Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Fineline Cube Sep 8, 2026
Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Fineline Cube Sep 8, 2026
Company Drug

Jiangxi Jemincare’s JYB1907 Receives NMPA Approval for Clinical Study in Solid Tumors

Fineline Cube Jun 16, 2023

China-based Jiangxi Jemincare Group has announced that it has received approval from the China National...

Company Medical Device

NMPA Approves Suzhou MicroPort Joint Medical Technology’s Zirconium Niobium Alloy Femoral Head for Hip Replacement

Fineline Cube Jun 16, 2023

The National Medical Products Administration (NMPA) has granted marketing approval to Suzhou MicroPort Joint Medical...

Company Drug

Cytocraft Biotech’s SDT-T002 Cell Therapy Approved for Advanced Liver Cancer by NMPA

Fineline Cube Jun 16, 2023

China-based Cytocraft Biotech Development has announced that its cell therapy, SDT-T002, has obtained clinical trial...

Company Deals

Laekna Raises £791 Million in Hong Kong IPO for Pipeline Expansion

Fineline Cube Jun 16, 2023

Sino-US Laekna (HKG: 2105) has successfully raised £791 million through an initial public offering (IPO)...

Company Drug

Grand Pharmaceutical’s STC3141 Achieves Clinical Endpoint in Sepsis Study

Fineline Cube Jun 16, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that the Phase Ib REFINE study...

Company

Everest Medicines Appoints Dr. Mike Berry as Chief Technology Officer to Drive Innovation

Fineline Cube Jun 16, 2023

China-based Everest Medicines (HKG: 1952) has announced the appointment of Dr. Mike Berry as Chief...

Company Legal / IP

AbbVie Inc. Files Lawsuit Against BeiGene Over BTK Inhibitor Brukinsa

Fineline Cube Jun 15, 2023

US-based AbbVie Inc., (NYSE: ABBV), the company behind the first-in-class Bruton’s tyrosine kinase (BTK) inhibitor...

Company Drug

Janssen Submits Additional Indication Application to FDA for Carvykti in Multiple Myeloma

Fineline Cube Jun 15, 2023

The Janssen subsidiary of Johnson & Johnson (J&J; NYSE: JNJ) has submitted an additional indication...

Company Drug

Dartsbio Pharmaceuticals and SIMM Receive NMPA Approval for ADC DS001 Clinical Trial

Fineline Cube Jun 15, 2023

Guangdong-based antibody drug developer Dartsbio Pharmaceuticals has partnered with the Shanghai Institute of Materia Medica...

Company Deals

Hubei Guangji Pharmaceutical Partners with Jiangnan University for Green Manufacturing Innovation Lab

Fineline Cube Jun 15, 2023

China-based Hubei Guangji Pharmaceutical Co., Ltd. (SHE: 000952) has announced a strategic partnership with Jiangnan...

Company Drug

Hybio Pharmaceutical’s Semaglutide API Receives FDA Review Acceptance

Fineline Cube Jun 15, 2023

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced that the US Food and Drug...

Company Deals

YSB Inc. Lists on HKSE with HKD 363.6 Million IPO, Targeting Digital Pharma Services

Fineline Cube Jun 15, 2023

China-based ex-hospital digital pharmaceutical service platform YSB Inc. (HKG: 9885) has successfully made its initial...

Company Drug

Ascletis Pharma Inc. Ceases Promotion of Hepatitis C Products and Halts Development of ASC06 and ASC09

Fineline Cube Jun 15, 2023

China-based Ascletis Pharma Inc., (HKG: 1672) has announced significant business adjustments, including the decision to...

Company Drug

Mabwell Bioscience’s IL-11 mAb 9MW3811 Receives US FDA Clinical Trial Approval

Fineline Cube Jun 15, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has received clinical...

Policy / Regulatory

NHSA Report Highlights ‘Flying Inspections’ Impact on Medical Insurance Fund Use in 2022

Fineline Cube Jun 14, 2023

The National Healthcare Security Administration (NHSA) has released a report outlining the outcomes of ‘flying...

Company Drug

Hansoh Pharmaceutical Gets NMPA Approval for HIF-2α Inhibitor HS-10516 Clinical Study

Fineline Cube Jun 14, 2023

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that it has received approval...

Company Deals

Sino Biopharmaceutical Secures Exclusive Rights to Gmax Biopharm’s GMA106 in Greater China

Fineline Cube Jun 14, 2023

Sino Biopharmaceutical Ltd (HKG: 1177) through its subsidiary Chia Tai Tianqing Pharmaceutical Co., Ltd, has...

Company

UIH Surgical to Invest RMB 2.5 Billion in Wuhan Medical Innovation and Robotics Base

Fineline Cube Jun 14, 2023

United Imaging Healthcare Technology Co., Ltd (UIH), through its subsidiary UIH Surgical, has announced plans...

Company Deals Medical Device

JJET’s IPO on STAR Market Accepted, Aims to Raise RMB 2.691 Billion for Medical Device Expansion

Fineline Cube Jun 14, 2023

China-based JJET has received acceptance for its Initial Public Offering (IPO) filing on the Shanghai...

Company Drug

Genevector Initiates Clinical Study for JWK001 in Neovascular Age-Related Macular Degeneration

Fineline Cube Jun 14, 2023

Chengdu-based adeno-associated virus (AAV) gene therapy developer, Genevector Biotechnology Co., Ltd., has announced the first...

Posts pagination

1 … 566 567 568 … 718

Recent updates

  • Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections
  • China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback
  • Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation
  • CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally
  • Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Company Deals

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

Company Deals

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.